ACAD vs. BHC, ARWR, RARE, MRTX, IONS, CTLT, ELAN, INSM, ROIV, and ASND
Should you be buying ACADIA Pharmaceuticals stock or one of its competitors? The main competitors of ACADIA Pharmaceuticals include Bausch Health Companies (BHC), Arrowhead Pharmaceuticals (ARWR), Ultragenyx Pharmaceutical (RARE), Mirati Therapeutics (MRTX), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Elanco Animal Health (ELAN), Insmed (INSM), Roivant Sciences (ROIV), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical preparations" industry.
Bausch Health Companies (NYSE:BHC) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk, community ranking and dividends.
ACADIA Pharmaceuticals has a net margin of -0.21% compared to ACADIA Pharmaceuticals' net margin of -5.07%. Bausch Health Companies' return on equity of -0.41% beat ACADIA Pharmaceuticals' return on equity.
Bausch Health Companies has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500.
Bausch Health Companies presently has a consensus target price of $11.33, indicating a potential upside of 72.76%. ACADIA Pharmaceuticals has a consensus target price of $28.94, indicating a potential upside of 91.64%. Given Bausch Health Companies' stronger consensus rating and higher possible upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Bausch Health Companies.
ACADIA Pharmaceuticals received 526 more outperform votes than Bausch Health Companies when rated by MarketBeat users. Likewise, 72.96% of users gave ACADIA Pharmaceuticals an outperform vote while only 61.90% of users gave Bausch Health Companies an outperform vote.
78.7% of Bausch Health Companies shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 8.1% of Bausch Health Companies shares are held by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
ACADIA Pharmaceuticals has lower revenue, but higher earnings than Bausch Health Companies. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.
In the previous week, Bausch Health Companies had 1 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 8 mentions for Bausch Health Companies and 7 mentions for ACADIA Pharmaceuticals. Bausch Health Companies' average media sentiment score of 0.38 beat ACADIA Pharmaceuticals' score of -0.13 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.
Summary
ACADIA Pharmaceuticals beats Bausch Health Companies on 13 of the 18 factors compared between the two stocks.
Get ACADIA Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ACADIA Pharmaceuticals Competitors List
Related Companies and Tools
